Eli Lilly (LLY)
930.35
-58.77 (-5.94%)
NYSE · Last Trade: Mar 17th, 8:30 PM EDT
These companies are benefiting from a tidal wave of demand for new weight-loss drugs.
Via The Motley Fool · March 17, 2026

Today, March 17, 2026, selective tech gains helped lift the Nasdaq even as oil prices and geopolitical tensions stayed elevated.
Via The Motley Fool · March 17, 2026
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 6.3% in the afternoon session after investment bank HSBC downgraded the stoc...
Via StockStory · March 17, 2026
You don't have to go all in to profit from AI.
Via The Motley Fool · March 17, 2026
Which S&P500 stocks are moving on Tuesday?chartmill.com
Via Chartmill · March 17, 2026
The analyst’s new price target represents a potential downside of about 14% from the stock’s last closing price on Monday.
Via Stocktwits · March 17, 2026

Eli Lilly's stock price is based on growth rates that might fall short.
Via The Motley Fool · March 17, 2026
Tuesday's session: top gainers and losers in the S&P500 indexchartmill.com
Via Chartmill · March 17, 2026
HSBC downgrades Eli Lilly to reduce, citing pricing pressure, rising competition, and overestimated obesity drug market growth expectations.
Via Benzinga · March 17, 2026
Novo Nordisk recently announced promising trial results for one of its GLP-1 drugs in development.
Via The Motley Fool · March 17, 2026
Tuesday's session: gap up and gap down stock in the S&P500 indexchartmill.com
Via Chartmill · March 17, 2026
Pfizer has reached a turning point.
Via The Motley Fool · March 17, 2026
Eli Lilly's stock is down this year, and its high valuation may be a big reason why.
Via The Motley Fool · March 16, 2026
Amidst a backdrop of mounting geopolitical tensions and sharp swings in the broader indices, pharmaceutical giant Merck & Co. (NYSE: MRK) officially trades ex-dividend today, March 16, 2026. Investors who held the stock prior to today’s session are now locked in to receive a quarterly payout of $0.85 per
Via MarketMinute · March 16, 2026
The drama and uncertainty around Novo Nordisk and Hims & Hers Health might finally be ending.
Via The Motley Fool · March 16, 2026
Eli Lilly's Phase 3 results for Ebglyss in children with severe eczema, shows skin clearance and itch relief in trial patients.
Via Benzinga · March 16, 2026
Quality compounders are flywheels. Said differently, they’re businesses that generate heaps of profits and consistently reinvest them to produce even more pr...
Via StockStory · March 16, 2026

This biotech firm develops therapies targeting cystic fibrosis, with shares up nearly 90% year-over-year as of the latest filing.
Via The Motley Fool · March 15, 2026

RAPT Therapeutics develops oral therapies for cancer and inflammation, with key drug candidates currently in clinical trials.
Via The Motley Fool · March 15, 2026
Via MarketBeat · March 15, 2026
It won't be easy to knock the company off its pedestal.
Via The Motley Fool · March 13, 2026
As the first quarter of 2026 unfolds, the euphoric bull market that defined the mid-2020s has hit a formidable wall of uncertainty. A potent cocktail of geopolitical instability in the Middle East and South America, coupled with a domestic crisis of confidence in central bank leadership, has sent major indices
Via MarketMinute · March 13, 2026
In a day marked by heightened global tensions and a sharp spike in energy prices, the U.S. equity markets witnessed a decisive "Great Rotation" as investors abandoned high-growth technology names in favor of battle-tested stalwarts. On Friday, March 13, 2026, JPMorgan Chase & Co. (NYSE: JPM) and Eli Lilly and
Via MarketMinute · March 13, 2026